MET is overexpressed in up to 60% of NSCLC cases, and in tumors harboring MET mutations this molecular structure is directly targeted using tyrosine kinase inhibitors (TKI) for therapeutic purposes [3]. The gene discussed is MET; the disease is non-small cell lung carcinoma.